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METHODS: This cross-sectional study was conducted in the UK, France (FR), and 
Germany (DE), with data collected via a representative European online volunteer/
opt-in panel (called “MRops”). A 34-minute survey was ﬁ elded to 500 subjects with 
T2DM who were currently receiving pharmacotherapy in each country (n = 1500) 
from December 2007 to January 2008. Survey items asked about weight, concerns 
about weight and health, and health-related well-being and function as assessed by 
the SF-12® Health Survey. RESULTS: Based on self-reported height and weight, 85% 
(UK), 71% (FR), and 86% (DE) were overweight or obese. Weight was noted as the 
most important current health concern by 19% (UK), 19% (FR), and 21% (DE). Not 
all respondents (88% (UK), 79% (FR), 82% (DE)) indicated a desire to lose weight. 
More subjects with T2DM in DE were “very much” distressed (27%) by their weight 
than subjects in UK and FR (both 18%). However, the percentage who were “very 
much” worried about their health because of their weight (UK [20%], FR [14%], DE 
[21%]) and “very much” embarrassed by their weight (UK [12%] FR [16%] DE 
[11%]) was similar across countries. Health-related well-being and function, as 
assessed by the SF-12®, was worse across all domains in those with higher body mass 
index (BMI) and those with greater weight-related distress, worry, and embarrass-
ment. CONCLUSIONS: Results indicate that elevated BMI and perceptions about 
weight affect health-related well-being and function as assessed by the SF-12®. Thera-
peutic options that help people with T2DM to lose weight may have a positive impact 
on patient lives.
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BACKGROUND: Health-related quality of life (HRQoL) is a multidimensional 
concept that provides insight regarding the impact of a disease from the patient’s 
perspective and yield an important health outcome to evaluate treatment interventions 
and quality of health care. OBJECTIVES: The goal of this study is to reveal HRQoL 
of type 2 diabetes mellitus (T2DM) patients treated in the Brazilian private health care 
system. METHODS: A generic instrument to assess health status (EuroQol—EQ-5D), 
commonly used in diabetic patients worldwide, was applied in 383 outpatients with 
T2DM from ﬁ ve cities (Fortaleza, Porto Alegre, Rio de Janeiro, Ribeirão Preto e São 
Paulo). Euroqol uses ﬁ ve dimensions to describe HRQoL states (mobility, self-care, 
usual activities, pain/discomfort, anxiety/depression) and a visual analogue scale (VAS) 
recorded by the patient and was measured during only one time during the visit to 
the physician. RESULTS: The group was composed of 201 women and 182 men, aged 
60.5 ± 9.6 years, mean BMI 29.1 kg/m2 and mean duration of diabetes of 12.2 ± 8.75 
years. For the entire group, mean EQ VAS score was 75.15 ± 16.72, 24.5% reported 
some problems with mobility, 4.2% with self-care, 17.5% problems in their usual 
activities, 44.9% any pain/discomfort and 45.2% anxiety/depression. Mean EQ VAS 
score decreased as diabetes duration increased (78.19 < 9 years vs. 73.26 > 19 years 
of disease; P = 0.05). The patients without micro and macrovascular complications 
(41.5%) had a higher VAS compared to those with these complications (18%) (VAS 
77.5 vs. 70.19; P = 0.002). Retinopathy (VAS = 68.13) and heart failure (VAS = 67.05) 
were conditions associated with lower EQ VAS scores. Regarding the type of treat-
ment, VAS was lower in insulin-treated patients compared to oral agents users (VAS 
= 76.59 vs. 71.54; P = 0,00004). CONCLUSIONS: A longer duration of diabetes, the 
presence of chronic complications and the use of insulin showed a negative impact on 
T2DM patient’s HRQoL.
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OBJECTIVES: Aim of this study was to evaluate the quality of medical treatment of 
diabetes patients and its trends in the Czech Republic and to compare the ﬁ ndings 
with the international research. Based on IDF prevalence of diabetes was 9,7% in 
2007 and is expected to rise to 11,7% in 2025. METHODS: Data were extracted 
from Czech cross-sectional studies from 2002 and 2007 and from European-based 
studies. Follow-up of short term parameters of quality of health care (HbA1c, BMI, 
blood pressure, lipids, treatment algorithms) which help to predict long-term incidence 
of complications. Frequency of microvascular and macrovascular complications was 
also assessed and the data were compared to statistics of the Czech Institute for Health 
Information and Statistics. RESULTS: Concerning short-term parameters there is wide 
variation accross European countries. We have not found signiﬁ cant differences 
between CR and selected European countries although there is insufﬁ cient evidence 
in revealing end-point values, e.g. HbA1c (7,7% in CR vs. 7,8% in Great Britain), 
BMI (29,9 in CR vs. 28,7 CODE-2 study) and reaching of target HbA1c values 
(36–42% in CR vs. 36% in CODE-2). 74% of Czech patients compared with 50% 
European patients are treated with metformin. Percentage of patients using antihyper-
tention drugs (83%) and hypolipidemics (63%) is similar in CR and the European 
average. The diabetic patients are reaching the tagret therapeutic values only in minor-
ity of cases (31% in systolic blood pressure, 27% in total cholesterol and in 36% of 
HbA1c). There is high prevalence of diabetic macrovascular and microvascular com-
plications (CHD = 49%, stroke = 9,3%, nephropathy = 28,3%, retinopathy = 25%, 
diabetic foot = 4,6%). CONCLUSIONS: This comparative analysis is the ﬁ rst example 
of systematic evaluation of the quality of health care concerning diabetes patients in 
CR. The future objective is to set proper quality indicators and follow them on con-
tinuous basis. 
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OBJECTIVES: This study aimed to investigate in people with type 2 diabetes (T2D) 
the relative willingness-to-pay (WTP) for different diabetes drug therapies based on 
outcomes of clinical trials with liraglutide. METHODS: WTP for diabetes drug 
therapy of people with T2D was assessed by combining results from a meta-analysis 
of liraglutide compared with other diabetes drug therapies in the liraglutide clinical 
development program (LEAD) and a survey on WTP for important aspects of diabetes 
medication in people with T2D. a meta-analysis of six randomised trials with 3967 
subjects in the LEAD program compared efﬁ cacy and safety of liraglutide, a once-daily 
human glucagon-like peptide-1 (GLP-1) analogue, vs. rosiglitazone, glimepiride, 
insulin glargine, and exenatide. The WTP survey had 461 participants with T2D from 
Sweden and used a discrete choice experiment methodology to evaluate convenience 
and clinical effects of treatments in T2D. Results were converted from SEK to c (10.14 
SEK/c). RESULTS: Combining meta-analysis and WTP results revealed that people 
with T2D preferred liraglutide to all comparators. They were willing to pay an extra 
c2.49/day for liraglutide 1.2 mg compared with rosiglitazone, c1.82/day compared to 
glimepiride, c3.17/day compared to insulin glargine, and c0.74/day compared to 
exenatide. For the comparisons with rosiglitazone, glimepiride and insulin glargine, 
the largest component was based on the additional weight improvements with lira-
glutide. Compared to exenatide, the largest component of preference was administra-
tion of the drug. CONCLUSIONS: WTP for liraglutide by people with T2D was 
noticeably higher compared to other standard therapies based on the clinical results 
from the meta-analysis. Primary drivers were weight decrease (compared to rosigli-
tazone, glimepiride and insulin glargine) and administration (compared to exenatide). 
In total, people were willing to pay up to c3.17/day more to use liraglutide 1.2 mg 
rather than use other glucose lowering treatments.
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OBJECTIVES: The duration of treatment with NPH, as a ﬁ rst insulin medication in 
type 2 diabetes is reported to be shorter than that of insulin glargine, with comparisons 
of glargine and insulin detemir inconsistent. We investigated whether differences 
remained after adjustment for potential confounders, including baseline HbA1c, and 
which factors are associated with longer duration of use of ﬁ rst insulin. METHODS: 
People on two or three oral glucose-lowering agents (OGLA) with poor glycaemic 
control who started long-term insulin treatment (2000–2007) were grouped by insulin 
type, NPH, glargine or detemir, and followed until a prescription for a different insulin 
or a GLP-1 mimetic. Time to treatment change was compared between groups in a 
Cox model adjusting for baseline characteristics: HbA1c, age, sex, year, time from 
diagnosis, concomitant OGLA, glomerular ﬁ ltration rate, cardio- and micro-vascular 
medical history and cardiovascular risk factors. The association of this duration with 
baseline characteristics and mean treatment HbA1c was investigated by univariate 
analyses. All data came from THIN database of electronic UK primary care records. 
RESULTS: The analysis included 1044 people started on glargine therapy; 187 on 
detemir and 453 on NPH. Compared to glargine the adjusted hazard ratios for time 
to treatment change were 1.78 (95%CI 1.43, 2.20) for detemir and 1.52 (1.29, 1.80) 
for NPH. Lower mean HbA1c with any insulin type was associated with longer time 
to change of regimen (Spearman rank correlation coefﬁ cient −0.30, P < 0.001). No 
concomitant OGLA use, increasing age and time from diagnosis, decreasing BMI and 
baseline HbA1c and heart failure were also associated with longer ﬁ rst insulin duration. 
CONCLUSIONS: People who commenced insulin treatment with glargine remained 
on their initial insulin for longer than those who initiated detemir or NPH after adjust-
ment for potential confounders. Better glycaemic control resulted in a longer time to 
change of insulin.
